Trial reportDrug delivery2022
Magnesium ascorbyl phosphate vesicular carriers for topical delivery; preparation, in-vitro and ex-vivo evaluation, factorial optimization and clinical assessment in melasma patients.
Trial report in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Development and evaluation of a propolis, tea tree oil, and jojoba oil nanoemulgel with enhanced antioxidant, anti-inflammatory, and wound-healing activities.Scientific reports · 2026Article
- Innovations in Refractory Melasma: Mechanism-Based Management and Emerging Therapeutic Strategies.Cureus · 2026Review
- Innovative Nanocarriers: Elastic Aspasomes Loaded with Metformin Hydrochloride for Effective Management of Melasma: In Vitro Studies and Clinical Appraisal.Pharmaceutics · 2026Article
- High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges.Genes & diseases · 2026Review
- Niosomes as Vesicular Nanocarriers in Cosmetics: Characterisation, Development and Efficacy.Pharmaceutics · 2025Review
- The Pathogenesis of Oxidative Stress-Induced Chloasma and Its Therapeutic Implications.Clinical, cosmetic and investigational dermatology · 2025Review
- Energy-Based Methods and Nanocarrier-Based Approaches for Melasma Treatment.Advanced pharmaceutical bulletin · 2024Review
- Recent Trends in the Development and Application of Nano-Antioxidants for Skin-Related Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Maximizing the Use of Ivermectin Transethosomal Cream in the Treatment of Scabies.Pharmaceutics · 2024Article
- Duo photoprotective effect via silica-coated zinc oxide nanoparticles and Vitamin C nanovesicles composites.Pharmaceutical research · 2024Article
- A Comprehensive Review on Niosomes as a Strategy in Targeted Drug Delivery: Pharmaceutical, and Herbal Cosmetic Applications.Current drug delivery · 2024Review
- A turn-on chemiluminescent assay for alkaline phosphatase using two-dimensional Fe-centered metal-organic frameworks as the signaling probe.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023Article
- New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective.ACS omega · 2023Review
- Quantitative evaluation of sensitive skin by ANTERA 3DSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascorbic acid (vitamin C) is an antioxidant that is widely used in cosmetics in skincare products. Due to the excessive low stability of ascorbic acid in cosmetic formulations, the stabilized ascorbic acid derivative, magnesium ascorbyl phosphate (MAP) was formulated as vesicular carriers; ethosomes and niosomes. The aim was to deliver MAP at the intended site of action, the skin, for sufficient time with enhanced permeation to get an effective response. Ethosomes were formulated using a full 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.